The third-phase clinical trial of the anti-viral drug ‘Remdesivir’, led by an Indian-American physician, to treat people infected with the coronavirus has yielded positive results. California-based pharmaceutical company Gilead Sciences said on Wednesday that preliminary results showed that 50 percent of COVID-19 patients’ condition improved after a five-day dose of the Remdesivir drug, and more than half of them received it for two weeks. Discharged within
Subrahmanyan said that additional results are needed, these results are a clear help in understanding how ‘Remedesivir’ can be treated if it proves to be safe and effective. The pharmaceutical company also said that it is aware of the positive results revealed by the study of the National Institute of Allergy and Infectious Diseases (NIAID) related to the anti-viral drug Remedisvir for the treatment of COVID-19.
It said that we feel that the test has achieved its initial objective and NIAID will provide detailed information in the upcoming briefing. Remedesivir drug has not yet received any approval or license in the world, nor has it been proven to be safe or effective in the treatment of COVID-19.
The company said it would soon share additional information about Phase III results on COVID-19 patients. At the same time, a study report published in the medical journal ‘Lancet’ said that in the treatment of COVID-19, the first randomized trial of the anti-viral drug Remedisivir has not found any significant therapeutic benefits. The study was conducted by China-Japan Friendship Hospital and Capital Medical University in China, which included 237 people admitted to hospitals in Wuhan.
Researchers say that Remedisivir was originally developed for the treatment of Ebola and has been designed to prevent viruses from forming themselves within the body.